Diabetes mellitus type 2(T2DM)is a common chronic metabolic disease,compared to non-diabetics,T2DM patients have a higher risk of heart disease,and their risk of vascular diseases is twice that of non-diabetic individu-als.Multiple clinical trials have confirmed that glucagon-like peptide-1 receptor agonists(GLP-1RA),in addition to their function of lowering blood glucose,can also decrease the risk of cardiovascular events in T2DM patients.This article re-views the mechanisms of GLP-1RA-mediated cardioprotection.It provides a comprehensive review of the recent progress in GLP-1RA-mediated cardiac protective mechanisms,elaborating on the protective effects of GLP-1RA on specific heart cell and further discussing its impact on heart failure(HF),provide assistance for clinical treatment of diabetic cardiomyopathy.

Diabetes mellitus type 2(T2DM)is a common chronic metabolic disease,compared to non-diabetics,T2DM patients have a higher risk of heart disease,and their risk of vascular diseases is twice that of non-diabetic individu-als.Multiple clinical trials have confirmed that glucagon-like peptide-1 receptor agonists(GLP-1RA),in addition to their function of lowering blood glucose,can also decrease the risk of cardiovascular events in T2DM patients.This article re-views the mechanisms of GLP-1RA-mediated cardioprotection.It provides a comprehensive review of the recent progress in GLP-1RA-mediated cardiac protective mechanisms,elaborating on the protective effects of GLP-1RA on specific heart cell and further discussing its impact on heart failure(HF),provide assistance for clinical treatment of diabetic cardiomyopathy.